Emaglin 25 mg (Tablet)

Title

• Emaglin 25 mg Tablet

Categories

• Medicine
• Diabetes
• Cardiovascular
• Pharmacology
• Therapeutic Class
• Pregnancy & Lactation
• Precautions & Warnings
• Storage Conditions
• Chemical Structure
• Common Questions

Description

• Adjunct to diet and exercise for type 2 diabetes mellitus
• Reduction of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
• SGLT-2 inhibitor
• Reduces renal absorption of glucose
• Increases glucose excretion
• Assists weight loss
• Lowers blood pressure
• Recommended dosage of 10 mg once daily
• Can be increased to 25 mg once daily
• Contraindicated in patients with hypersensitivity reaction to Empagliflozin, severe renal impairment, end-stage renal disease, or dialysis
• Common side effects include urinary tract infections, female genital mycotic infections, dehydration, hypotension, weakness, dizziness, and increased thirstiness
• Should be used cautiously in patients with underlying kidney disease
• No dose adjustment needed for patients with mild to moderate liver disease
• Chemical structure: C23H27ClO7
• Storage below 30°C, protected from light & moisture, keep out of the reach of children

Indications

• Improving glycemic control in adults with type 2 diabetes mellitus
• Reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Pharmacology

• Sodium glucose co-transporter-2 (SGLT-2) inhibitor
• Reduces renal absorption of glucose
• Increases glucose excretion
• Assists weight loss
• Lowers blood pressure

Dosage & administration

• Recommended dose of 10 mg once daily, taken in the morning, with or without food
• Dose may be increased to 25 mg once daily for patients tolerating Empagliflozin
• Corrections of volume depletion recommended prior to initiation in patients

Interactions

• Diuretics: Co-administration with diuretics increases urine volume
• Insulin or Insulin Secretagogues: Co-administration increases the risk for hypoglycemia
• Positive Urine Glucose Test: SGLT2 inhibitors increase urinary glucose excretion, leading to positive urine glucose tests
• Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended

Contraindications

• Hypersensitivity reaction to Empagliflozin or any of its ingredients
• Severe renal impairment
• End-stage renal disease
• Dialysis

Side effects

• Urinary tract infections
• Female genital mycotic infections
• Dehydration
• Hypotension
• Weakness
• Dizziness
• Increased thirstiness

Pregnancy & lactation

• Use during pregnancy only if potential benefit justifies potential risk to the fetus
• Not recommended during breastfeeding as excretion in human milk is not known

Precautions & warnings

• Assessment of renal function recommended prior to initiation and periodically thereafter
• Not initiated in patients with eGFR less than 45 ml/min/1.73 m2
• No dose adjustment needed in patients with eGFR greater than or equal to 45 ml/min/1.73 m2

Overdose effects

• Usual supportive measures should be employed
• Removal by hemodialysis not studied

Therapeutic class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage conditions

• Keep in a cool & dry place (below 30°C)
• Protected from light & moisture
• Keep out of the reach of children

Chemical structure

• Molecular Formula: C23H27ClO7

Common questions

• What is Emaglin 25 mg Tablet?
• What is Emaglin 25 mg Tablet used for?
• Pregnancy warnings
• Breast-feeding warnings
• Effect on kidney function
• Effect on liver function
• Quick Tips: Usage, dehydration, hypoglycemia, hygiene, blood sugar monitoring, and reporting symptoms

Related Brands